Evidence map›Paper›PMID 40678536›Full record

ArticleiScience2025

Application of sentinel lymph nodes biopsy tracers for breast cancer after neoadjuvant chemotherapy in China: A multicenter, real-world study.

Fengjiang Qu, Tinghan Jiang, Zhenzhen Liu, Rui Ling, Yi Zhao, Hongjian Yang, Yunjiang Liu, Ke Liu, Jianguo Zhang, Dahua Mao and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Fengjiang QuDepartment of Emergency Surgery, The First Hospital of Jilin University, Changchun, Jilin Province 130021, China.
Tinghan JiangMinistry of Education, The First Hospital of Jilin University, Changchun, Jilin Province 130021, China.
Zhenzhen LiuDepartment of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan Province 450008, China.
Rui LingDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Yi ZhaoSurgical Oncology Department, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
Hongjian YangDepartment of Breast Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang Province 310022, China.
Yunjiang LiuDepartment of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
Ke LiuFourth Department of Breast Surgery, Jilin Cancer Hospital, Changchun, Jilin Province, China.
Jianguo ZhangDepartment of Breast Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, China.
Dahua MaoDepartment of Breast Surgery, Affiliated Wudang Hospital of Guizhou Medical University, Guiyang, Guizhou Province 550009, China.
Jianjun HeDepartment of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710061, China.
Zhigang YuDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province 250033, China.
Yinhua LiuBreast Disease Center, Peking University First Hospital, Beijing 100034, China.
Peifen FuDepartment of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310003, China.
Jiandong WangDepartment of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing 100852, China.
Hongchuan JiangDepartment of Breast Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
Zuowei ZhaoDepartment of Breast Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province 116023, China.
Xingsong TianDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China.
Zhongwei CaoDepartment of Thyroid, Breast, Hernia Surgery, The Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia Autonomous Region 010017, China.
Kejin WuDepartment of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Ailin SongDepartment of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province 730000, China.
Feng JinDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Di WuDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin Province 130021, China.
Zhimin FanDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin Province 130021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The real-world application of tracers for axillary sentinel lymph node biopsy (SLNB) for breast cancer (BC) after neoadjuvant chemotherapy (NAC) in China was unknown. We analyzed the use of individual tracers or combinations and number of SLNs in patients with BC who underwent SLNB with or without axillary lymph node dissection (ALND) after NAC in 20 hospitals in ten years. A total of 1251 BC patients underwent SLNB or SLNB + ALND after NAC, including 853 (68.2%, 853/1251) with a single tracer, predominantly Methylene blue (MB) (60.1%, 752/1251); and 398 (31.8%, 398/1251) with dual tracers, mainly MB combined with radioisotope (RI) (18.1%, 226/1251).The results showed that the predominance of the MB single-tracer method for SLNB after NAC limits the popularity of SLNB in patients with BC after NAC in China. MB combined with RI is the main dual-tracer method, and detects SLNs more effectively than MB alone.

Indexed as

diagnostic procedurediagnosticsoncology

Identifiers

PMID40678536
PMCPMC12270654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.